- Home
- LIXT vs KTTA Comparison
LIXT vs KTTA Comparison
Compare LIXT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- KTTA
- Stock Information
- Founded
- LIXT 2005
- KTTA 2020
- Country
- LIXT United States
- KTTA United States
- Employees
- LIXT N/A
- KTTA N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- KTTA Health Care
- Exchange
- LIXT Nasdaq
- KTTA Nasdaq
- Market Cap
- LIXT 3.0M
- KTTA 2.8M
- IPO Year
- LIXT N/A
- KTTA 2021
- Fundamental
- Price
- LIXT $0.74
- KTTA $0.73
- Analyst Decision
- LIXT
- KTTA
- Analyst Count
- LIXT 0
- KTTA 0
- Target Price
- LIXT N/A
- KTTA N/A
- AVG Volume (30 Days)
- LIXT 82.2K
- KTTA 222.0K
- Earning Date
- LIXT 08-07-2025
- KTTA 08-12-2025
- Dividend Yield
- LIXT N/A
- KTTA N/A
- EPS Growth
- LIXT N/A
- KTTA N/A
- EPS
- LIXT N/A
- KTTA N/A
- Revenue
- LIXT N/A
- KTTA N/A
- Revenue This Year
- LIXT N/A
- KTTA N/A
- Revenue Next Year
- LIXT N/A
- KTTA N/A
- P/E Ratio
- LIXT N/A
- KTTA N/A
- Revenue Growth
- LIXT N/A
- KTTA N/A
- 52 Week Low
- LIXT $0.64
- KTTA $0.71
- 52 Week High
- LIXT $3.00
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- LIXT 30.79
- KTTA 33.06
- Support Level
- LIXT $0.64
- KTTA $0.71
- Resistance Level
- LIXT $0.93
- KTTA $0.80
- Average True Range (ATR)
- LIXT 0.13
- KTTA 0.04
- MACD
- LIXT -0.05
- KTTA 0.00
- Stochastic Oscillator
- LIXT 16.99
- KTTA 12.14
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).